Linda A Buss1, Anishah Mandani1, Elisabeth Phillips1, Nicola J A Scott2, Margaret J Currie1, Gabi U Dachs3. 1. Mackenzie Cancer Research Group, Department of Pathology, University of Otago, Christchurch, New Zealand. 2. Christchurch Heart Institute, Department of Medicine, University of Otago, Christchurch, New Zealand. 3. Mackenzie Cancer Research Group, Department of Pathology, University of Otago, Christchurch, New Zealand gabi.dachs@otago.ac.nz.
Abstract
BACKGROUND/AIM: Patients with breast cancer and metabolic syndrome have poorer outcomes. We aimed to develop and characterise an apolipoprotein E-null/aromatase knockout (ApoE-/-/ArKO) mouse model of breast cancer with metabolic syndrome to aid research of the mechanisms behind poor prognosis. MATERIALS AND METHODS: Wild-type, ApoE-/- and ApoE-/-/ArKO mice were orthotopically implanted with EO771 murine breast cancer cells. Tumour growth was monitored and tumours investigated for pathological features such as cancer-associated adipocytes, hypoxia and cancer cell proliferation. RESULTS: Tumours from ApoE-/-/ArKO mice were significantly more proliferative than those from wild-type mice (p=0.003), and exhibited reduced expression of insulin-like growth factor binding protein-5 (p=0.002). However, ApoE-/-/ArKO mice also had a reduced rate of metastasis compared to wild-type and ApoE-/- mice. Tumour hypoxia and the number of cancer-associated adipocytes did not differ. CONCLUSION: The ApoE-/-/ArKO model with EO771 breast cancer provides a novel mouse model to investigate the effects of metabolic syndrome on aspects of breast tumour biology. Copyright
BACKGROUND/AIM: Patients with breast cancer and metabolic syndrome have poorer outcomes. We aimed to develop and characterise an apolipoprotein E-null/aromatase knockout (ApoE-/-/ArKO) mouse model of breast cancer with metabolic syndrome to aid research of the mechanisms behind poor prognosis. MATERIALS AND METHODS: Wild-type, ApoE-/- and ApoE-/-/ArKO mice were orthotopically implanted with EO771 murinebreast cancer cells. Tumour growth was monitored and tumours investigated for pathological features such as cancer-associated adipocytes, hypoxia and cancer cell proliferation. RESULTS:Tumours from ApoE-/-/ArKO mice were significantly more proliferative than those from wild-type mice (p=0.003), and exhibited reduced expression of insulin-like growth factor binding protein-5 (p=0.002). However, ApoE-/-/ArKO mice also had a reduced rate of metastasis compared to wild-type and ApoE-/- mice. Tumour hypoxia and the number of cancer-associated adipocytes did not differ. CONCLUSION: The ApoE-/-/ArKO model with EO771 breast cancer provides a novel mouse model to investigate the effects of metabolic syndrome on aspects of breast tumour biology. Copyright
Authors: Chun-Te Chen; Yi Du; Hirohito Yamaguchi; Jung-Mao Hsu; Hsu-Ping Kuo; Gabriel N Hortobagyi; Mien-Chie Hung Journal: Mol Cancer Ther Date: 2012-07-23 Impact factor: 6.261
Authors: Erik R Nelson; Suzanne E Wardell; Jeff S Jasper; Sunghee Park; Sunil Suchindran; Matthew K Howe; Nicole J Carver; Ruchita V Pillai; Patrick M Sullivan; Varun Sondhi; Michihisa Umetani; Joseph Geradts; Donald P McDonnell Journal: Science Date: 2013-11-29 Impact factor: 47.728
Authors: Elizabeth J Campbell; Margreet C M Vissers; Christina Wohlrab; Kevin O Hicks; R Matthew Strother; Stephanie M Bozonet; Bridget A Robinson; Gabi U Dachs Journal: Free Radic Biol Med Date: 2016-08-24 Impact factor: 7.376
Authors: P Workman; E O Aboagye; F Balkwill; A Balmain; G Bruder; D J Chaplin; J A Double; J Everitt; D A H Farningham; M J Glennie; L R Kelland; V Robinson; I J Stratford; G M Tozer; S Watson; S R Wedge; S A Eccles Journal: Br J Cancer Date: 2010-05-25 Impact factor: 7.640